Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8454406 | Lung Cancer | 2017 | 9 Pages |
Abstract
We found levels of 4 metabolites, caffeine, paraxanthine, stachydrine, and methyl glucopyranoside (alpha + beta), differed significantly between NSCLC patients with poor and good survival in both discovery and validation phases (P < 0.05). Interestingly, majority of the identified metabolites are involved in caffeine metabolism, and 2 metabolites are related to coffee intake. In fact, caffeine metabolism pathway was the only significant pathway identified which significantly differed between NSCLC patients with poor and good survival (P = 1.48E-07) in the pathway analysis. We also found 4 metabolites whose levels were significantly associated with good survival in both discovery and validation phases. Strong cumulative effects on overall survival were observed for these 4 metabolites. In conclusion, we identified a panel of metabolites including metabolites in caffeine metabolism pathway that may predict survival outcome in advanced-stage NSCLC patients. The identified small metabolites may be useful biomarker candidates to help identify patients who may benefit from platinum-based chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jie Shen, Yuanqing Ye, David W. Chang, Maosheng Huang, John V. Heymach, Jack A. Roth, Xifeng Wu, Hua Zhao,